Joe
12-15-2005, 10:52 AM
Received this email today !!
Joe
http://www.huginonline.dk/MEB/logo.gif (http://www.pharmexa.com/)
Published: 13:21 15.12.2005 GMT+1 /HUGIN /Source: Pharmexa A/S /CSE: PHARMX /ISIN: DK0015966592
The first patients have begun treatment in Pharmexa's current phase II trial with HER-2 Protein AutoVac(TM) in combination with the adjuvant QS-21
Summary: The first patients have begun treatment in Pharmexa's phase II trial with HER-2 Protein AutoVac(TM) in combination with the adjuvant QS-21. The trial is proceeding satisfactorily and follows the timetable.</B>
Pharmexa has received notification that the first patients have been vaccinated at the study sites in Poland. Patients in the phase II trial with HER-2 Protein AutoVac(TM) in combination with the adjuvant QS-21 will receive four initial immunisations over a six week period with 1.25 milligram HER-2 Protein AutoVac(TM) formulated with Alhydrogel adjuvant and mixed with QS-21 adjuvant, followed by booster immunisations every four week for up to 26 weeks. The trial will be carried out at 10-15 cancer research centres in Poland, Romania and Russia. According to plan the centres will recruit 40 patients with active HER-2 positive breast cancer.
Hørsholm, December 15, 2005
Jakob Schmidt
Chief Executive Officer
Additional information:
Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525
Note to editors: Pharmexa A/S [CSE: PHARMX] is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary technology platforms are broadly applicable, but the company has focused its resources on cancer and chronic inflammatory diseases, with research and development programs targeted towards various cancer forms, rheumatoid arthritis, bone degeneration, Alzheimer's disease and others. Its leading programs are GV1001, a peptide vaccine about to enter phase III trials in pancreatic cancer and HER-2 AutoVac Protein, a recombinant protein vaccine in phase II against breast cancer. Collaborative agreements include Schering-Plough, H. Lundbeck and Bavarian Nordic. Pharmexa recently announced the acquisition of certain assets related to the former Epimmune operation in San Diego, USA. This acquisition is expected to be formally closed before the end of the year.
This press release was brought to you by Hugin, distributor of electronic press releases for companies listed on selected European stock exchanges. Address: http://www.huginonline.com/Denmark/PHARMX (http://www.huginonline.com/Denmark/PHARMX)
To alter your subscription profile, please go to: http://www.huginonline.com/email (http://www.huginonline.com/email)
To unsubscribe: http://www.huginonline.com/unsubscribe (http://www.huginonline.com/plsql/try/unsubscribe.unsub)
The Hugin Team
Joe
http://www.huginonline.dk/MEB/logo.gif (http://www.pharmexa.com/)
Published: 13:21 15.12.2005 GMT+1 /HUGIN /Source: Pharmexa A/S /CSE: PHARMX /ISIN: DK0015966592
The first patients have begun treatment in Pharmexa's current phase II trial with HER-2 Protein AutoVac(TM) in combination with the adjuvant QS-21
Summary: The first patients have begun treatment in Pharmexa's phase II trial with HER-2 Protein AutoVac(TM) in combination with the adjuvant QS-21. The trial is proceeding satisfactorily and follows the timetable.</B>
Pharmexa has received notification that the first patients have been vaccinated at the study sites in Poland. Patients in the phase II trial with HER-2 Protein AutoVac(TM) in combination with the adjuvant QS-21 will receive four initial immunisations over a six week period with 1.25 milligram HER-2 Protein AutoVac(TM) formulated with Alhydrogel adjuvant and mixed with QS-21 adjuvant, followed by booster immunisations every four week for up to 26 weeks. The trial will be carried out at 10-15 cancer research centres in Poland, Romania and Russia. According to plan the centres will recruit 40 patients with active HER-2 positive breast cancer.
Hørsholm, December 15, 2005
Jakob Schmidt
Chief Executive Officer
Additional information:
Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525
Note to editors: Pharmexa A/S [CSE: PHARMX] is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary technology platforms are broadly applicable, but the company has focused its resources on cancer and chronic inflammatory diseases, with research and development programs targeted towards various cancer forms, rheumatoid arthritis, bone degeneration, Alzheimer's disease and others. Its leading programs are GV1001, a peptide vaccine about to enter phase III trials in pancreatic cancer and HER-2 AutoVac Protein, a recombinant protein vaccine in phase II against breast cancer. Collaborative agreements include Schering-Plough, H. Lundbeck and Bavarian Nordic. Pharmexa recently announced the acquisition of certain assets related to the former Epimmune operation in San Diego, USA. This acquisition is expected to be formally closed before the end of the year.
This press release was brought to you by Hugin, distributor of electronic press releases for companies listed on selected European stock exchanges. Address: http://www.huginonline.com/Denmark/PHARMX (http://www.huginonline.com/Denmark/PHARMX)
To alter your subscription profile, please go to: http://www.huginonline.com/email (http://www.huginonline.com/email)
To unsubscribe: http://www.huginonline.com/unsubscribe (http://www.huginonline.com/plsql/try/unsubscribe.unsub)
The Hugin Team